𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cytogenetic analysis of de novo CD5-positive diffuse large B-cell lymphoma

✍ Scribed by Hiroto KANEKO; Kazuho SHIMURA; Shigeo HORIIKE; Junya KURODA; Yosuke MATSUMOTO; Shohei YOKOTA; Koichi NISHIDA; Yasuo OHKAWARA; Masafumi TANIWAKI

Book ID
111318914
Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
82 KB
Volume
7
Category
Article
ISSN
1743-7555

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Analysis of chromosomal imbalances in de
Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization
✍ Sivasundaram Karnan; Hiroyuki Tagawa; Ritsuro Suzuki; Miyuki Suguro; Motoko Yama πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 107 KB

We recently demonstrated that the prognosis for de novo CD5-positive (CD5+) diffuse large-B-cell lymphoma (DLBCL) is markedly worse than that for CD5-negative (CD5-) DLBCL. Our findings also suggested that on the basis of its clinical features CD5+ DLBCL may constitute a unique disease category. How

Cytogenetic features of de novo CD5-posi
Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: Chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival
✍ Tomoko Yoshioka; Ikuo Miura; Masaaki Kume; Naoto Takahashi; Masataka Okamoto; Ry πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 257 KB

## Abstract De novo CD5‐positive diffuse large B‐cell lymphoma (CD5^+^DLBCL) is regarded as a different clinicopathological entity from CD5‐negative DLBCL (CD5^βˆ’^DLBCL) and mantle cell lymphoma (MCL). Because only a few published cytogenetic studies of de novo CD5^+^DLBCL are available, we investig

The therapeutic effect of rituximab on C
The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma
✍ Rie Hyo; Naoto Tomita; Kengo Takeuchi; Tomohiro Aoshima; Atsuko Fujita; Hideyuki πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 111 KB

## Abstract The prognosis of diffuse large B‐cell lymphoma (DLBCL) has improved markedly in recent years of rituximab era. The prognosis of __de novo__ CD5‐positive DLBCL is reported to be poor, but the effect of rituximab on this type of lymphoma remains unclear. To investigate the effect of ritux